The FDA’s recently unveiled plausible mechanism framework may have been forged with i | The FDA’s newly launched plausible ...
Advanced breeding tools and data-driven insights are helping farmers get more yield, consistency and value from every acre.
A compact Cas12f nuclease shows high editing efficiency in human cells, with structural insights enabling an engineered variant potentially suited for future AAV‑compatible delivery.
DPA International on MSN
Biohacking: Cracking your body's 'feel-good code'
The term "biohacking" can conjure up futuristic notions of envelope-pushing self-optimization, gene editing and subdermal ...
The US Food and Drug Administration (FDA) has released draft guidance on how sponsors can utilize next-generation sequencing ...
Morning Overview on MSN
Ultrasound-triggered nanoparticles create light in tissue for therapy
Delivering light to a tumor buried centimeters inside the body has always required threading a fiber-optic cable through ...
The CRISPR-Cas gene-editing system has long been the focus of research as a promising tool in genome editing. However, the ...
In 2025, baby KJ Muldoon became the first person to receive a personalized gene editing treatment, which likely saved his ...
The draft guidance supports the agency’s new pathway designed to speed up the development of custom gene therapies.
Scientists have taken an important step toward a gene therapy that could one day turn off the extra genetic material that ...
The document outlines the non-clinical sequencing and bioinformatics data sponsors need to submit as part of INDs and BLAs for gene-editing therapies.
The document outlines the non-clinical sequencing and bioinformatics data sponsors need to submit as part of INDs and BLAs for gene-editing therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results